For 4QFY2016, Cadila Healthcare (Cadila) posted a robust performance on the
net profit front while sales came in lower than expected. Sales came in at
Rs2,376cr (V/s Rs2,400cr expected), growing by 5.7% yoy. On the operating front,
the OPM came in at 21.4% V/s 21.1% expected and V/s 20.2% in 4QFY2015.
The expansion in the OPM was driven by expansion in the GPM to 65.4% (V/s
64.3% in 4QFY2015) despite increase in staff expenditure and other expenditure
by 13.7% yoy 3.8% yoy respectively. R&D expenditure during the quarter came in
at 7.6% V/s 8.4% of sales in 4QFY2015. The Adj. net profit came in at Rs388cr V/s
Rs373cr expected and V/s Rs351cr in 4QFY2015, ie a yoy growth of 10.6%. We
maintain our Buy on the stock.
Results better than expected at the net profit level: For 4QFY2016, sales came in
at Rs2,342cr (V/s Rs2,400cr expected), growing by 5.7% yoy. On the operating
front, the OPM came in at 21.4% V/s 21.1% expected and V/s 20.2% in
4QFY2015. The expansion in the OPM was driven by expansion in the GPM to
65.4% (V/s 64.3% in 4QFY2015) and despite 13.7% yoy growth in the staff
expenditure and 3.8% yoy rise in other expenditure. R&D expenditure during the
quarter came in at 7.6% V/s 8.4% of sales in 4QFY2015. The Adj. net profit came
in at Rs388cr V/s Rs351cr in 4QFY2015, a yoy growth of 10.6%.
Outlook and valuation: We expect Cadila’s net sales to post a 17.8% CAGR to
Rs13,148cr and EPS to report a 15.8% CAGR to Rs20.0 over FY2016–18E. We
maintain our Buy rating on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...